- Home
- MBAV vs ESPR Comparison
MBAV vs ESPR Comparison
Compare MBAV & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- ESPR
- Stock Information
- Founded
- MBAV 2024
- ESPR 2008
- Country
- MBAV United States
- ESPR United States
- Employees
- MBAV N/A
- ESPR N/A
- Industry
- MBAV
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- ESPR Health Care
- Exchange
- MBAV NYSE
- ESPR Nasdaq
- Market Cap
- MBAV 359.4M
- ESPR 319.2M
- IPO Year
- MBAV 2024
- ESPR 2013
- Fundamental
- Price
- MBAV $10.00
- ESPR $2.16
- Analyst Decision
- MBAV
- ESPR Buy
- Analyst Count
- MBAV 0
- ESPR 4
- Target Price
- MBAV N/A
- ESPR $8.17
- AVG Volume (30 Days)
- MBAV 41.9K
- ESPR 3.2M
- Earning Date
- MBAV 01-01-0001
- ESPR 11-05-2024
- Dividend Yield
- MBAV N/A
- ESPR N/A
- EPS Growth
- MBAV N/A
- ESPR N/A
- EPS
- MBAV N/A
- ESPR N/A
- Revenue
- MBAV N/A
- ESPR $277,788,000.00
- Revenue This Year
- MBAV N/A
- ESPR $205.39
- Revenue Next Year
- MBAV N/A
- ESPR $21.69
- P/E Ratio
- MBAV N/A
- ESPR N/A
- Revenue Growth
- MBAV N/A
- ESPR 215.98
- 52 Week Low
- MBAV $9.97
- ESPR $0.70
- 52 Week High
- MBAV $10.15
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- ESPR 68.72
- Support Level
- MBAV N/A
- ESPR $1.58
- Resistance Level
- MBAV N/A
- ESPR $1.74
- Average True Range (ATR)
- MBAV 0.00
- ESPR 0.13
- MACD
- MBAV 0.00
- ESPR 0.05
- Stochastic Oscillator
- MBAV 0.00
- ESPR 98.31
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.